(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
7 December 2000 (07.12.2000)

PCT

(10) International Publication Number
WO 00/72853 A1

(51) International Patent Classification[7]: A61K 33/22 // (A61K 33/22, 33:14, 31:135)

(21) International Application Number: PCT/RO99/00014

(22) International Filing Date: 23 September 1999 (23.09.1999)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
99-00605 26 May 1999 (26.05.1999) RO

(71) Applicants and
(72) Inventors: NICULESCU, Corneliu, M. [RO/RO]; Intrarea Castor 6, G4, ap 42, Ploieşti, R-judeţ Prahova (RO).

NICULESCU, Corneliu, C. [RO/RO]; Str. Turda 33, Sector 1, R-Bucureşti (RO).

(74) Common Representative: NICULESCU, Corneliu, C.; Str. Turda 33, Sector 1, R-Bucuresti (RO).

(81) Designated States *(national)*: CA, IL, TR, US, ZA.

(84) Designated States *(regional)*: European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).

Published:
— *With international search report.*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 00/72853 A1

(54) Title: CHEMICAL COMPOSITION, FABRICATION PROCEDURE AND TREATMENT METHODOLOGY BASED ON IT, AS CANCER MEDICATION

(57) Abstract: The present invention refers to a chemical medicament, a fabrication procedure and medication methodology based thereon, in case of cancer. The medicine comprises boric acid, which replaces phosphoric acid in the cell nucleus, procaine hydrochloride, which unbalances the metabolism of cancer-affected cell by free radical control, and a normal saline solution as the circulating medium. The active ingredients of the product thus modify the abnormal metabolism of cancer cells, determining their destruction. As chemotherapy, this innovation leads to cancer cell cytolysis without being toxic to the human body. Furthermore, it allows a parallel classical cancer medication, thereby positively influencing the latter.

INVENTION DESCRIPTION

The object of invention refers to:
CHEMICAL COMPOSTION, FABRICATION PROCEDURE AND TREATMENT METHODOLOGY BASED ON IT, AS CANCER MEDICATION.

Appliance range of the product is cancer disease medication as a chemoterapy treatment.
Cancer chemoterapy also known as cytostatics enables the evolution delay of different neoplasical affections.
Actual cytostatic treatment available is no longer effective in all cancer cell locations and stages of development. Generally speaking, haematopoetic tissue cancer is relatively sensible and cancer tumor hardly sensible to chemoterapy, which does not save the patient life but scarcely improve his condition for an certain period of time, as additional medication beside the specific classical cancer treatment (surgery and radiotherapy) .Cytostatics do not destroy the cancer cell but slow down its evolution.
The above mentioned substances are toxic, having side haematological effects, the harmful effects entailing mouth and intestine mucous membranes lesion, lever lesions, baldness, hypogonadism and immunology weakening which develop proper conditions for infections spreading. Furthermore, the price of these products is significantly high.
As a counter-part to those previously analyzed, our product develops an effective treatment of all cancer disease locations and its stages of evolution. It stands either as a single medication or together with any other classical medication, highly improving it to the benefit of the patient.

CHEMICAL COMPOSITION OF THE PRODUCT

1. Sodium chloride	9000 mg
2. Chlorine hydrate of 4 aminobenzoilethyleaminoethanole	200-300mg
1. Boric acid	700-800mg
2. Distilled water	1000 ml

The above composition has the important advantage of not being toxic.
The procaine chlorine hydrate dose allowed for 24 hours is of 250 mg, boric acid dose being of 3,000 mg
Toxic noxious dose of procaine chlorine hydrate is of 2,500 mg and of boric acid of 8,000 mg.
Medication doses of our product are as follows: 18mg of procaine chlorine hydrate per day and 54 mg boric acid per day
Concluding, our product may be included within hemaeopatic medication products lacking toxicity.

It is well known the fact that cancer cell induces deviations usually at nucleic acid level resulting in a mutation of genetic information, which determines the incapacity to control the cell metabolism and implicitly cells sizes and multiplication.
Consequently for this uncontrolled development, the cancer cell needs additional phosphoric acid (acid standing for the basis of nucleic acids) which is absorbed in very large quantities, even if its level in human organism is generally low.

We reached the conclusion that the boric acid replaces the phosphoric acid within the cancer cell metabolism, being , let us say, fond of it destroying it.
The normal cells of human body, other than cancer affected ones, do not mistake the identification of the two acids, therefore they are not affected.

It is notorious that procaine chlorine hydrate has an anesthetic effect, determines blood vessel expansion, controls the plane muscles, enhances the tissues nutrition and it is a inter - cell free radicals inhibitor. Cancer cells as well as ordinary old cells have a higher concentration of free radicals - idea agreed by dr. ASLAN as well when she introduced procaine chlorine hydrate in the composition of GEROVITAL.
Free radicals inhibition inside the cancer cell leads to a significant lowering of its vitality, as well as of its secretions, noxious to the organism.
We consider it as well causes the cancer cell to mistake the identification of boric acid instead of phosphoric acid, and determines self-destruction.

PRODUCT FABRICATION PROCEDURE

9000 mg of sodium chloride is dissolved into 1000 ml of distilled water.
The solution is heated into a vessel up to 60 C degrees and 250 mg of procaine chlorine hydrate is added, stir for the solution homogenization; further to, the temperature is raised up to 90-95 C degrees (care shall be paid not to reach the boiling temperature), the 750 mg of boric acid is added, continuously stirring the solution. After dissolving the compounds and cooling of the solution, pH value of 6.5 is checked and controlled by adding a small quantity of boric acid (in case the distilled water has a neutral pH value the control is no longer required).
The product such obtained is filled into properly clean bottles, not reacting with the product acidity (as a preference, food approved containers, dark colored or light-tight).
Product is best over 1 year, seal tight kept at a temperature 0f 10-20 C degrees, light tight, as it is a light sensitive product. Lacking to follow these safety conditions leads to flocs development, annihilating is properties.

TREATMENT METODOLOGY

The product is recommended in all cancer locations and stages of disease either as a single medication or together with any other classical treatment (surgery or chemotherapy).
The product medication is oral, following the quantities:
30 ml (two tablespoon) in the morning, 30 ml at noon and 15 ml (one tablespoon) in the evening, at least 20 minutes before having the respective meals.
During this 20 minutes period no liquid drinking is allowed.
The treatment lasts two years, no matter the fact that the disease symptoms disappeares mean time and the laboratory tests and other medical investigations prove to have normalized the health condition.
Even a 24 hours discontinuity of the medication may lead to negative evolution of the healing process, determining the involution of healing with several months.
As concerns the treatment discontinuity of several days period, it may lead to the complete inefficiency of the previous appliance of the treatment, and the disease may reinstall after several years. We specify that the respective medication is no longer effective in this case.

The medication is associated with Poliglin muscle injected, one ampoule per day in series of 3 days consecutively at a period of 2 weeks distance and Vitamin C 200mg daily for own immunity system stimulation

SUMARY

The hereunto invention refers to a chemical medicament. a fabrication procedure and medication methodology on its basis. in case of cancer diagnostic
The active ingredients of the product modify the abnormal metabolism of cancer cell. determining its destruction

As chemeoterpy. this innovation determines the production of cancer cell cytolysis. without being toxic to the human body and which allows parallel cancer classical medication furthermore it determines a positive influence of classical medication

CLAIMS

I. The hereunto described product is a cancer treating medicine · action is characterized by cancer affected cell destruction through the replacement of a basic acid contained into the cell nucleus, namely, the phosphoric acid is replaced by boric acid contained by our product. Proc chlorine hydrate unbalances the metabolism of the cancer-affected cell t radical control thus lowering the cell discrimination and allowing it to mat two acids.

The normal saline solution represents the circulating medium fc active substances and facilitates their penetration into the cancer-affecte osmosis. The low acid pH of the product does not determine gastric juice intestine reaction and enables the product to reach neoplasical location unmodified.

The product attacks the tumor from the outside to inside, begin with the healing of metastasis stage down to the prime tumor, annihilatin all the young cancer cells, then proceeding with the others.

II. Preparation procedure of the product characteristically consists normal saline solution and procaine chlorehydrate 0.250 % at a temperal 60 C degree homogenization and boric acid 0.750 % at a temperature of C degrees (avoiding reaching the boiling temperature). After cooling, the value will be controlled, if case, by adding boric acid.

The product is to be kept at room temperature – 10-20 C degre dark places (as it is photosensitive), it is highly stable in time under the th conditions being best over 1 year

III.The product characteristic medication is oral, as follows: 30 ml soupspoons) in the morning, 30 ml at noon and 15 ml (one soupspoon) ii evening, 20 minutes before having the respective meals, during this 20 n period neither liquid nor solid food is allowed.

The medication is compulsory for 2 years long, no matter the stage of the disease and, clinical and laboratory results normalization. Th medication stopping even for 24 hours, during the 2 years period, may le treatment ineffectiveness when restarted.

The medication is associated with Polidin in series of 3 days period of 2 weeks, one ampoule per day and Vitamin C 200 mg daily for i immunity system stimulation

INTERNATIONAL SEARCH REPORT

Intern. nal Application No
PCT/RO 99/00014

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61K33/22 //(A61K33/22,33:14,31:135)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	FR 2 459 659 A (CENTRALA IND MEDICAMENTE) 16 January 1981 (1981-01-16) the whole document	1-3
A	DATABASE WPI Week 199840 Derwent Publications Ltd., London, GB; AN 1998-459642 XP002133589 JUHASZ BENEDEK: "Process for producing pharmaceutical composition for treating neoplasmic syndromas" & HU 9 601 450 A (JUHASZ BENEDEK), 28 June 1998 (1998-06-28) abstract	1-3

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
21 March 2000	31/03/2000

Name and mailing address of the ISA	Authorized officer
European Patent Office, P.B. 5818 Patentlaan 2 NL – 2280 HV Rijswijk Tel. (+31–70) 340–2040, Tx. 31 651 epo nl, Fax: (+31–70) 340–3016	Cielen, E

Form PCT/ISA/210 (second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/RO 99/00014

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
FR 2459659 A	16-01-1981	RO 72294 A	06-12-1982
		CA 1142855 A	15-03-1983
		DE 3023396 A	22-01-1981
		ES 492468 D	16-05-1981
		ES 8104912 A	01-08-1981
HU 9601450 A	29-06-1998	NONE	